Le Lézard
Classified in: Health, Covid-19 virus
Subject: SVY

Insights on the Rheumatoid Arthritis Diagnosis Tests Global Market to 2027 - Featuring Antibodies Inc, Beckman Coulter & Siemens Healthineers Among Others


DUBLIN, Sept. 29, 2020 /PRNewswire/ -- The "Rheumatoid Arthritis Diagnosis Tests - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The publisher brings years of research experience to the 8th edition of this report. The 276-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Global Rheumatoid Arthritis Diagnosis Tests Market to Reach $852.8 Million by 2027

Amid the COVID-19 crisis, the global market for Rheumatoid Arthritis Diagnosis Tests estimated at US$599.9 Million in the year 2020, is projected to reach a revised size of US$852.8 Million by 2027, growing at a CAGR of 5.2% over the period 2020-2027.

Serology Tests, one of the segments analyzed in the report, is projected to record 5.5% CAGR and reach US$630.2 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Monitoring RA Treatment Efficiency Tests segment is readjusted to a revised 4.3% CAGR for the next 7-year period.

The U.S. Market is Estimated at $162.5 Million, While China is Forecast to Grow at 7.8% CAGR

The Rheumatoid Arthritis Diagnosis Tests market in the U.S. is estimated at US$162.5 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$176.8 Million by the year 2027 trailing a CAGR of 7.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.8% and 4.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Competitors identified in this market include, among others:

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/dj41ta

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.


Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 17:31
DelveInsight's Urine Output Monitoring Systems Market Insights report provides the current and forecast market analysis, individual leading urine output monitoring systems companies' market...

at 17:00
Enghouse Video, a global leader in cutting-edge video technology solutions, today announced its partnership with SONIFI Health, enhancing virtual care in hospital settings. SONIFI Health is a leading U.S. healthcare technology company based in Sioux...

at 17:00
A record 3,618 graduating students and physicians matched to residency training programs in Canada in this year's R-1 Main Residency Match (R-1 match), the Canadian Resident Matching Service (CaRMS) announced today....

at 16:54
Hondros College of Nursing (HCN) will introduce a new Medical Assisting program at its six Ohio campuses in 2024 to meet the growing need for medical assistants in a variety of settings.  According to the U.S. Bureau of Labor Statistics (BLS),...

at 16:45
Halozyme Therapeutics, Inc. ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services. "Mahesh is a dynamic and...

at 16:35
Geron Corporation , a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the market opens on Thursday, May 2, 2024 via press release, which will...



News published on and distributed by: